A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
Orr ME, Kotkowski E, Ramirez P, et al. (2023). GeroScience.
Summary
A pilot whose main purpose was safety: twenty older adults with mild cognitive impairment took nicotinamide riboside or placebo for ten weeks, building up to a fixed daily intake. The primary outcome was change on a standard cognitive screening test, with cerebral blood flow, blood NAD+ levels and further neurocognitive and physical tests as secondary measures, and DNA methylation as an exploratory one. Twenty people over ten weeks is a safety and feasibility study, not a test of whether the supplement helps cognition.